Treatment decisions in systemic lupus erythematosus.
Rheumatologists and nephrologists were surveyed, by the use of specifically designed case histories, regarding their management of selected aspects of systemic lupus erythematosus (SLE). Treatment was individualized on a case by case basis by the vast majority of respondents. There was agreement on the initial treatment of SLE involving mild arthritis, active nephritis, or central nervous system disease and on steroid tapering practices. There was disagreement about treatment of a "serologic flare" and the management of late-stage nephropathy. Academic centers were more selective and less aggressive than practicing subspecialists. Areas of concordance document current standard treatment practices but sometimes show dissociation between the degree of consensus and the level of available medical knowledge.
D001168:Arthritis / Q000188:drug therapy / Q000209:etiology; D001241:Aspirin / Q000627:therapeutic use; D002493:Central Nervous System Diseases / Q000188:drug therapy / Q000209:etiology; D003657:Decision Making; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy*; D008511:Medicine; D009393:Nephritis / Q000188:drug therapy / Q000209:etiology; D011241:Prednisone / Q000627:therapeutic use; D013038:Specialization; D011795:Surveys and Questionnaires
D007166:Immunosuppressive Agents; D001241:Aspirin; D011241:Prednisone